Engineering the Eye IV Restoring Vision
眼睛工程 IV 恢复视力
基本信息
- 批准号:8785777
- 负责人:
- 金额:$ 1.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressBlindedBrainConeDevelopmentDevicesDiseaseElectrodesElectronicsEngineeringEuropeEyeFellowshipForm PerceptionFutureGeneticGoalsHumanImplantLaboratory AnimalsLengthLifeLightMediatingMethodologyMethodsMotionNeuronal PlasticityOcular ProsthesisPathologyPatientsPerceptionPeripheralPlayPluripotent Stem CellsPostdoctoral FellowPreventionProsthesisPublicationsRecoveryResearchResearch PersonnelRetinaRetinal Ganglion CellsRiskRoleScientistSpecialistStem cellsStudentsTechniquesTechnologyTestingTimeTravelUnited StatesViral VectorVisionVision DisordersVision researchVisualVisual PathwaysVisual PerceptionVisual impairmentWorkbaseblinddeprivationelectronic visual prosthesisgene therapyimplantationlight gatedluminancemeetingsposterspublic health relevancerestorationretinal neuronretinal prosthesisretinal rodssymposiumvision developmentvision sciencevisual information
项目摘要
DESCRIPTION (provided by applicant): Restoration of vision has long been a goal of vision research. It has been studied sporadically since the 1700s, but first produced effective vision restoration when arrays of stimulating electrodes were implanted into the brain, initially by Brindley in 1968 and subsequently by William Dobelle in the 1980s. Since that time, there has been rapid development of a wide range of methods for vision restoration, most of which have been examined only in laboratory animals. These include such diverse approaches as implantation of stem cells into retina and the insertion of light-gated channels into inner retinal
neurons. The restoration method that has had the most impact recently, however, is the implantation of electronic stimulation devices just below or above the retina, an approach which recently received CE Mark approval in Europe and FDA approval in the United States. The rapid progress in developing vision restoration technologies has resulted in conferences and publications on technical challenges facing each approach. However, there has been little direct comparison of which methods best meet the goals of vision restoration. Discussion between research groups involved with different approaches has been limited in part by the unique constraints on each methodology. For example, implantation of electronic retinal prostheses is routinely performed in blind humans, although much parallel research continues to examine electronic stimulation of retinal ganglion cells in laboratory animals. Human perception can be easily tested, thus this approach has been shown to produce perceptual benefits, unlike other methods such as viral vectors and pluripotent stem cells that involve great risks of pathology in humans and have therefore been conducted largely in laboratory animals. On the other hand, pluripotent stem cells and use of light sensitive prosthetics such as channelrhodopsin might provide important advantages over electronic prostheses, but analysis of this question requires clear identification of the goals of vision restoration. The 29th Symposium of the Center for Visual Science will bring vision restoration researchers together with low vision specialists who study the importance for daily living of such visual capabilities as: foveal versus peripheral vision, motion versus form perception, and high luminance cone versus low luminance rod mediated vision. It will examine vision restoration in light of the variety of disorders that damag vision and the type of information that partially or totally blind patients need to function normaly. It will also consider the role played by central visual pathways in restoring vision, limitations t recovery resulting from alteration of early visual development, and the importance of cortical plasticity in refinement of visual perception as patients adapt to their visual prosthesis. The conference will also provide an opportunity for students and post-docs to present their work in poster sessions, and will make competitive travel fellowships available to the best of the students and post- docs who wish to attend and present their work.
描述(由申请人提供):恢复视力长期以来一直是视力研究的目标。自 1700 年代以来,人们对其进行了零星的研究,但当布林德利 (Brindley) 于 1968 年、随后威廉·多贝尔 (William Dobelle) 在 1980 年代将刺激电极阵列植入大脑时,首次实现了有效的视力恢复。从那时起,各种视力恢复方法迅速发展,其中大多数仅在实验动物中进行了检查。其中包括多种方法,例如将干细胞植入视网膜以及将光门通道插入视网膜内部
神经元。然而,最近影响最大的修复方法是在视网膜正下方或上方植入电子刺激装置,这种方法最近获得了欧洲 CE 标志的批准和美国 FDA 的批准。视力恢复技术开发的快速进展催生了有关每种方法面临的技术挑战的会议和出版物。然而,对于哪种方法最能满足视力恢复目标,几乎没有直接比较。涉及不同方法的研究小组之间的讨论部分受到每种方法的独特限制的限制。例如,电子视网膜假体的植入通常在盲人身上进行,尽管许多平行研究仍在继续检查实验动物视网膜神经节细胞的电子刺激。人类感知可以很容易地进行测试,因此这种方法已被证明可以产生感知益处,这与病毒载体和多能干细胞等其他方法不同,这些方法在人类中涉及巨大的病理风险,因此主要在实验动物中进行。另一方面,多能干细胞和光敏感假体(例如视紫红质通道蛋白)的使用可能比电子假体具有重要优势,但分析这个问题需要明确视力恢复的目标。视觉科学中心第 29 届研讨会将把视力恢复研究人员与低视力专家聚集在一起,研究视觉能力对日常生活的重要性,例如:中央凹与周边视觉、运动与形状知觉、高亮度视锥细胞与低亮度视杆细胞介导的视觉。它将根据损害视力的各种疾病以及部分或完全失明的患者正常运作所需的信息类型来检查视力恢复情况。它还将考虑中央视觉通路在恢复视力中所发挥的作用、早期视觉发育改变导致的恢复限制,以及当患者适应视觉假体时皮质可塑性在改善视觉感知中的重要性。会议还将为学生和博士后提供在海报会议上展示其工作的机会,并将为希望参加并展示其工作的最优秀的学生和博士后提供有竞争力的旅行奖学金。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William H Merigan其他文献
Human V4?
- DOI:
10.1016/0960-9822(93)90340-t - 发表时间:
1993-04-01 - 期刊:
- 影响因子:
- 作者:
William H Merigan - 通讯作者:
William H Merigan
William H Merigan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William H Merigan', 18)}}的其他基金
Physiological and perceptual examination of vision restoration
视力恢复的生理和知觉检查
- 批准号:
10357890 - 财政年份:2011
- 资助金额:
$ 1.84万 - 项目类别:
Functional Imaging of Ganglion Cells in the Living Mammalian Eye
活体哺乳动物眼中神经节细胞的功能成像
- 批准号:
8021616 - 财政年份:2011
- 资助金额:
$ 1.84万 - 项目类别:
Physiological and perceptual examination of vision restoration
视力恢复的生理和知觉检查
- 批准号:
10576819 - 财政年份:2011
- 资助金额:
$ 1.84万 - 项目类别:
Functional Imaging of Ganglion Cells in the Living Mammalian Eye
活体哺乳动物眼中神经节细胞的功能成像
- 批准号:
8435519 - 财政年份:2011
- 资助金额:
$ 1.84万 - 项目类别:
Feasibility of an Optogenetic Prosthesis for the Primate Eye
灵长类动物眼睛光遗传学假体的可行性
- 批准号:
8632393 - 财政年份:2011
- 资助金额:
$ 1.84万 - 项目类别:
Functional Imaging of Ganglion Cells in the Living Mammalian Eye
活体哺乳动物眼中神经节细胞的功能成像
- 批准号:
8212083 - 财政年份:2011
- 资助金额:
$ 1.84万 - 项目类别:
Feasibility of an Optogenetic Prosthesis for the Primate Eye
灵长类动物眼睛光遗传学假体的可行性
- 批准号:
9004633 - 财政年份:2011
- 资助金额:
$ 1.84万 - 项目类别:
Functional Imaging of Ganglion Cells in the Living Mammalian Eye
活体哺乳动物眼中神经节细胞的功能成像
- 批准号:
8545257 - 财政年份:2011
- 资助金额:
$ 1.84万 - 项目类别:
Can light sensors, placed in ganglion cells, restore vision to a blind retina?
放置在神经节细胞中的光传感器能否恢复盲人视网膜的视力?
- 批准号:
7739334 - 财政年份:2009
- 资助金额:
$ 1.84万 - 项目类别:
Can light sensors, placed in ganglion cells, restore vision to a blind retina?
放置在神经节细胞中的光传感器能否恢复盲人视网膜的视力?
- 批准号:
7915440 - 财政年份:2009
- 资助金额:
$ 1.84万 - 项目类别:
相似海外基金
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 1.84万 - 项目类别:
Operating Grants
The effectiveness of oral cannabis extracts for osteoarthritic pain: an internal pilot, placebo controlled, blinded randomized trial
口服大麻提取物对骨关节炎疼痛的有效性:一项内部试点、安慰剂对照、盲法随机试验
- 批准号:
479511 - 财政年份:2023
- 资助金额:
$ 1.84万 - 项目类别:
Operating Grants
IMPACT, a supervised rehabilitation program for spastic ataxias: A rater-blinded, randomized controlled trial
IMPACT,痉挛性共济失调的监督康复计划:一项评估者盲法、随机对照试验
- 批准号:
468464 - 财政年份:2022
- 资助金额:
$ 1.84万 - 项目类别:
Operating Grants
Lineup construction methods: Should lineup constructors be blinded to the suspect?
阵容构建方法:阵容构建者是否应该对嫌疑人视而不见?
- 批准号:
2754233 - 财政年份:2022
- 资助金额:
$ 1.84万 - 项目类别:
Studentship
ZZ-3K3A-301: A multicenter, randomized, placebo-controlled, double-blinded, Phase 3 study to evaluate the efficacy and safety of 3K3A-APC (RHAPSODY-2)
ZZ-3K3A-301:一项多中心、随机、安慰剂对照、双盲、3 期研究,旨在评估 3K3A-APC (RHAPSODY-2) 的有效性和安全性
- 批准号:
10305528 - 财政年份:2022
- 资助金额:
$ 1.84万 - 项目类别:
Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons with Post-COVID-19 Condition
评估沃替西汀对 COVID-19 后患者认知缺陷的随机、双盲、安慰剂对照研究
- 批准号:
467059 - 财政年份:2021
- 资助金额:
$ 1.84万 - 项目类别:
Studentship Programs
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias
不同 α-突触核蛋白接种测定作为路易体痴呆皮肤生物标志物的盲法比较
- 批准号:
10458459 - 财政年份:2021
- 资助金额:
$ 1.84万 - 项目类别:
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias
不同 α-突触核蛋白接种测定作为路易体痴呆皮肤生物标志物的盲法比较
- 批准号:
10674759 - 财政年份:2021
- 资助金额:
$ 1.84万 - 项目类别:
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias
不同 α-突触核蛋白接种测定作为路易体痴呆皮肤生物标志物的盲法比较
- 批准号:
10064563 - 财政年份:2021
- 资助金额:
$ 1.84万 - 项目类别:
Discontinuation of levothyroxine therapy for patients with subclinical hypothyroidism: a pilot randomized, double-blinded, placebo-controlled study
亚临床甲状腺功能减退症患者停止左旋甲状腺素治疗:一项随机、双盲、安慰剂对照试验研究
- 批准号:
10337077 - 财政年份:2021
- 资助金额:
$ 1.84万 - 项目类别:














{{item.name}}会员




